Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Discussions on PMP Should Go Beyond Its Scope: JMA’s Imamura
November 10, 2017
- Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says
November 6, 2017
- EFPIA Japan Chief Urges Govt to Maintain Support for Innovation
November 2, 2017
- Boehringer’s Thorsten Poehl Named EFPIA Japan Vice Chairman
October 31, 2017
- Global Pharma CEOs Prod Japan to Keep Pro-Innovation Policy, Sound Alarm on Proposed PMP Review
October 31, 2017
- PhRMA, EFPIA Upping Lobbying Campaigns amid Drug Pricing Overhaul
October 30, 2017
- JPMA Reprimands Bayer over Side Effect Reporting Violation, Chides “Inappropriate” Promotion
October 20, 2017
- Securities Analysts Rank Shionogi No. 1 among Drug Markers for “Excellence in Disclosure”
October 17, 2017
- JMA President Yokokura Heads WMA
October 17, 2017
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- Taskforce Discussing Info-Sharing Between Drug Makers in Non-Competitive Fields: JPMA R&D Head
October 12, 2017
- Generic Use Rate at 67.8% in April-June: JGA
September 29, 2017
- Biologics Training Center to Start Human Resources Development in Biologics Field Next April
September 20, 2017
- Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
- Daiichi Sankyo’s Hirano to Replace Kamoya as Chuikyo Pharma Rep
September 11, 2017
- Plasma Fraction Products Should Remain in List of Essential Drugs: Blood Products Association Exec
September 11, 2017
- Introduce Permanent Price Maintenance Scheme, Don’t Rush on CEA Debate: UA Zensen
September 7, 2017
- JMA’s Imamura Questions Distribution Coefficient in Cost Calculation Formula
September 5, 2017
- LINK-J Expanding Free Consultation Service for Academic Researchers
August 31, 2017
- Cancer Advocate Warns of Lack of Patient Involvement in CEA Debates
August 30, 2017
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…